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Abstract 
Patients with chronic idiopathic Parkinson’s disease are at a high risk for fractures, 
particularly of the hip. The causes may be multifactorial, including poor balance and 
other forms of neurological dysfunction. Osteopenia and osteoporosis leading to 
decreased bone mass are common in these patients. We report a case of a male patient 
with a long-standing history of Parkinson’s disease on chronic high-dose carbidopa-
levodopa who suffered a hip fracture. The relationship of Parkinson’s disease and 
carbidopa-levodopa use with osteopenia and hip fractures is discussed, emphasizing the 
crucial need for prevention in this patient population along with medical and surgical 
treatment. 
 
Introduction 
Patients with idiopathic Parkinson’s disease (IPD) are at a high risk for hip fractures. 
The causes may be multifactorial, including poor balance and other forms of neurological 
dysfunction. People with IPD also have a high frequency of osteopenia and osteoporosis 
leading to decreased bone mass compounding the risk of fracture. This short case report 
discusses various mechanisms and highlights the crucial need for prevention in these 
patients along with treatment. 
Case Presentation 
A 55-year-old Caucasian male had a 14-year history of IPD with worsening dyskinesias alternating 
with spells of immobility, postural instability, and ‘wearing off’ phenomenon. He was in this usual state  
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of baseline neurologic health when he arose from his computer one morning, stumbled and fell. 
Emergency medical services were activated and the patient was transported to the emergency 
department of our hospital where he was found to have a right hip fracture. The patient was seen by 
orthopedics and underwent a successful right hip arthroplasty without incident. 
His past medical history was significant only for some depression and anxiety. There was no family 
history of IPD or any other progressive neurologic disorder. The patient had worked as a warehouse 
manager for a number of years until progression of his disease forced him to retire (about 5 years prior 
to his current presentation). There was no history of any illicit drug use. He did not smoke tobacco but 
reported alcohol use of 1 drink per month. 
The patient had been on high doses of carbidopa-levodopa (25–250 mg, 1.5 tablets every 2 h while 
awake) and a dopamine agonist (ropinirole 2 mg, 1 tablet every 2 h while awake) for his rigidity and 
amantadine (100 mg, 1 tablet every 5 h) for his dyskinesias for a number of years. 
Neurologic examination was remarkable for a patient in no acute distress. His right hip was in an 
immobilizer. He had prominent dyskinetic movements involving his arms, neck and face with 
hypophonic speech. Tone was increased in his bilateral upper extremities and finger-tapping amplitude 
was diminished. His mental status was quite intact, being able to recall objects and count backwards. No 
hallucinations or delusions were observed. No cranial nerve deficits were noted. Reflexes were intact at 
2/4 in the bilateral upper extremities and the left knee jerk. Motor strength testing was 5/5 (Medical 
Research Council Grade) in the bilateral upper extremities and the left lower extremity. Testing of the 
right lower extremity and gait was limited secondary to the post-operative hip immobilizer. There was 
no upper extremity dysmetria on finger-to-nose testing and sensation was intact to light touch, pain, 
and temperature throughout.  
Written informed consent was obtained from the patient for publication of this case report. 
 
Discussion 
Parkinson’s disease and osteoporosis are 2 disorders that affect a significant portion of 
patients. Patients with Parkinson’s disease have a high risk of hip fractures. The causes 
may be multifactorial, including poor balance and other forms of neurological 
dysfunction including bradykinesia and hypokinesis leading to falls. Osteopenia and 
osteoporosis leading to decreased bone mass are also common in these patients [1]. 
Osteoporosis is more common in IPD patients than in age-matched controls. Up to 
91% of females with IPD are found to have osteopenia or osteoporosis [1]. One of the 
main factors causing increased osteoporosis in these patients is decreased mobility 
leading to decreased weight-bearing exercise which is critical to maintain bone mass 
during aging. This lack of weight bearing causes increases bone reabsorption and 
decreases bone deposition. In addition, these patients are unstable and have an increased 
risk of falls. Besides bradykinesia and postural instability, both of which contribute to 
falls, autonomic instability further increases risk. It should be noted that autonomic 
instability may be a medication side effect – one that should be seriously considered 
before starting new medications in patients with IPD. One study has shown that dementia 
related to IPD increases fracture risk further, as these patients are less likely to be aware of 
their surroundings and physical limitations [2]. 
A 2007 study showed that levodopa is associated with an increased fracture risk, and 
that the risk is dose dependent. This correlation was greatest when analyzing hip fracture 
specifically [3]. Some believe that the increased fracture risk is due to the fact that 
levodopa increases patient mobility without improving postural stability, providing  
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increased opportunity for fall and fracture [4]. It has also been shown that anti-IPD 
medications, specifically L-dopa, increase serum homocysteine levels [5]. An elevated 
homocysteine level is an independent risk factor for fracture, regardless of the patient’s 
IPD status. 
Although IPD is a serious, progressive illness, one must not forget other clinical factors 
applicable to each individual patient that may change their risk stratification for fractures. 
Like all patients, increased age, female gender, low body mass, and vitamin D deficiency 
all increase fracture risk [1]. Any patient may have a variety of these risk factors along 
with the added factors associated with IPD. 
Because of the often debilitating nature of hip fractures, clinicians should do whatever 
possible to prevent fractures in the first place. It has been shown that vitamin D 
supplementation and bisphosphonate treatment can decrease fracture risk [1]. However, 
other studies show no statistically significant difference between those treated 
prophylactically with risedronate versus placebo [6]. It is important to note that even in 
this trial, where fracture risk was not greatly affected, bone mineral density was 
significantly better in the bisphosphonate group. Urine markers of bone resorption were 
also significantly improved, signifying a role for bisphosphonate prophylaxis in these 
patients. This study also included daily ergocalciferol treatment in both groups – which 
may help counter bone resorption in these patients. 
Regardless of the cause of hip fracture in IPD patients, these fractures do occur and 
require vigilant management. Many studies have postulated that these patients have an 
increased mortality when compared to controls without IPD; however, these studies have 
had conflicting results [4]. Initial clinical parameters influence a patient’s clinical course, 
such as age, gender, mobility, etc. From the orthopedic prospective, it is difficult to 
compare outcomes of IPD patients with hip fractures from other patients with hip 
fractures. Some studies suggest that 6-month mortality is similar for both groups, around 
14%, where other studies suggest IPD mortality is closer to 50% at 6 months [4]. 
Controversy also exists regarding how these fractures should be treated. Internal fixation 
appears to be a good option for patients with IPD; however, this is not always feasible 
when patients have a higher grade fracture. It is thought that endoprostheses for severe 
fractures are associated with poor outcomes in IPD because they delay mobility post-
operatively. 
Overall, this review of the literature illustrates that hip fractures are a large problem in 
the population of patients with IPD. It is important to counsel patients and family 
members about these risks, so they are aware of how they can prevent fractures in their 
home. In addition, it is an important issue for neurologists, orthopedists and primary care 
physicians to be aware of when seeing patients with IPD. It appears that controversy still 
exists regarding the best method of management for these fractures as well as long-term 
outcome. Although it is crucial for orthopedists dealing with hip fractures to learn the 
best course of treatment, even more emphasis should be placed on prevention. 
Conclusion 
Patients with IPD have a high risk of osteopenia and hip fractures. The causes are 
multifactorial. Treatment exists, but prevention is paramount.  
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